Eczema
-
Hawiger still blazing a trail in inflammation research
Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema. Read MoreNov 10, 2022